Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related changes in the immune system and challenges for the development of age-specific vaccines.

Annals of medicine·2025
Same author

Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.

Vaccine·2024
Same author

Modelling the Cost-Effectiveness of Hepatitis A in South Africa.

Vaccines·2024
Same author

Expanding the reach of vaccinology training in Africa: leveraging the success of the Annual African Vaccinology Course.

Frontiers in health services·2023
Same author

C-type lectin receptor agonists elicit functional IL21-expressing Tfh cells and induce primary B cell responses in neonates.

Frontiers in immunology·2023
Same author

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine.

Vaccines·2023

Related Experiment Video

Updated: Jun 12, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

New vaccines for tuberculosis.

Stefan H E Kaufmann1, Gregory Hussey, Paul-Henri Lambert

  • 1Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany. kaufmann@mpiib-berlin.mpg.de

Lancet (London, England)
|May 22, 2010
PubMed
Summary

New tuberculosis vaccines are crucial for reducing disease incidence by 2050. While promising candidates enter trials, long-term strategies are needed to eradicate the pathogen, offering significant return on investment.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Substantial reduction in tuberculosis incidence by 2050 necessitates novel vaccine development.
  • Despite increased funding, a significant financial gap persists in tuberculosis vaccine research and development.
  • Approximately ten vaccine candidates are currently in clinical trials, aiming to replace or augment the existing BCG vaccine.

Discussion:

  • Current pre-exposure vaccine candidates focus on disease prevention, not pathogen eradication or preventing stable infection.
  • Long-term vaccination strategies must address more ambitious goals, including complete pathogen elimination.
  • The development of new tuberculosis vaccines, while costly, promises substantial long-term economic benefits.

Key Insights:

  • Urgent need for new tuberculosis vaccines to meet 2050 reduction targets.
  • Clinical trials are underway for novel BCG-replacement or BCG-enhancing vaccines.
  • Existing candidates primarily offer disease prevention, highlighting the need for eradication-focused strategies.

Outlook:

  • Future vaccine development should prioritize eradication and prevention of stable infection.
  • Sustained investment in tuberculosis vaccine R&D is critical for global health security.
  • The long-term societal and economic returns of successful tuberculosis vaccines are projected to be significant.